GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadrenal Therapeutics Inc (NAS:CVKD) » Definitions » Retained Earnings

Cadrenal Therapeutics (Cadrenal Therapeutics) Retained Earnings : $-16.74 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Cadrenal Therapeutics Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Cadrenal Therapeutics's retained earnings for the quarter that ended in Mar. 2024 was $-16.74 Mil.

Cadrenal Therapeutics's quarterly retained earnings declined from Sep. 2023 ($-13.93 Mil) to Dec. 2023 ($-15.07 Mil) and declined from Dec. 2023 ($-15.07 Mil) to Mar. 2024 ($-16.74 Mil).

Cadrenal Therapeutics's annual retained earnings increased from . 20 ($0.00 Mil) to Dec. 2022 ($-6.71 Mil) but then declined from Dec. 2022 ($-6.71 Mil) to Dec. 2023 ($-15.07 Mil).


Cadrenal Therapeutics Retained Earnings Historical Data

The historical data trend for Cadrenal Therapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadrenal Therapeutics Retained Earnings Chart

Cadrenal Therapeutics Annual Data
Trend Dec22 Dec23
Retained Earnings
-6.71 -15.07

Cadrenal Therapeutics Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Retained Earnings Get a 7-Day Free Trial Premium Member Only -11.89 -12.89 -13.93 -15.07 -16.74

Cadrenal Therapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Cadrenal Therapeutics  (NAS:CVKD) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Cadrenal Therapeutics (Cadrenal Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
822 A1A North, Suite 306, Ponte Vedra, FL, USA, 32082
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
Executives
John Raymond Murphy director 233 S PATTERSON AVE, SPRINGFIELD MO 65802
Quang X Pham director, 10 percent owner, officer: CEO and Chairman 89 MELROSE DRIVE, MISSION VIEJO CA 92692
Robert Lisicki director C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Douglas W Losordo officer: Chief Medical Officer 13 FOX MEADOW RD, SCARSDALE NY 10583
Steven Zelenkofske director 120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920
Matthew K Szot officer: Chief Financial Officer 802 NORTH DOUTY STREET, HANFORD CA 93230
Glynn Wilson director 2483 NE JULEP STREET, ISSAQUAH WA 98029